Navigation Links
BioLegend Releases Brilliant Violet 421™ Antibody Conjugates For Advanced Flow Cytometry Applications.
Date:4/13/2011

SAN DIEGO, April 13, 2011 /PRNewswire/ -- BioLegend, Inc., a provider of antibodies and reagents for biomedical research, announced today the release of over fifty Brilliant Violet 421™ antibody conjugates for use in flow cytometry and microscopy.  BioLegend developed these reagents using Brilliant Violet 421™, the first in a series of novel polymer-based fluorophores developed by Sirigen from Nobel Prize-winning chemistry.  It is excited by the 405 nm violet laser, and detected with the 450/50 nm filter typically used for Pacific Blue™ and BD Horizon™ V450.  Brilliant Violet 421™ antibodies provide exceptional brightness, stability, reliability, and improved signal-to-noise over Pacific Blue™ by 10-fold or more. 

"Brilliant Violet 421™ will enable researchers to more clearly resolve populations in multi-color flow cytometry analysis," said Gene Lay, CEO of BioLegend.  "The brightness of BV421™ is on par with that of PE, providing an excellent dynamic range and making it a new first choice for researchers using the violet laser."  

Brilliant Violet 421™ antibodies are fully compatible with currently used buffers and fixatives, and common cell staining techniques, suitable for both surface and intracellular staining of antigens. Its narrow excitation and emission spectra result in less requirement for cross-beam compensation and compensation into neighboring detectors.  BioLegend plans to continue to expand this product line, providing more antibody specificities for mouse, rat and human research.  For more information, visit www.biolegend.com/brilliantviolet

About BioLegend:

BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services including assay development, sample testing, and conjugation. BioLegend was incorporated in June, 2002 with headquarters in San Diego, CA.

CONTACT:
Dzung Nguyen, Associate Director, Technical Marketing
BioLegend, Inc.
(858)768-5880
dnguyen@biolegend.com


'/>"/>
SOURCE BioLegend, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution
2. Aureus Pharma Releases New Unified Knowledge Database
3. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
4. Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials
5. Presidio Pay Advisors Releases Salary GPS Tool
6. Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009
7. BioWisdom Releases Text Analytics Version of OmniViz for Patent Specialists
8. T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture
9. BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
10. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
11. DynaVox Releases Software Version 1.05 for DynaVox V and Vmax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ROCKVILLE, Md. , March 24, 2017  Infectex ... Fund (MBVF), today announced positive results of a Phase ... drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... by scientists at Sequella, Inc. ( USA ... A total of 140 patients were enrolled ...
(Date:3/24/2017)... , March 24, 2017   Sienna Biopharmaceuticals, ... aesthetics company, today announced that Richard Peterson ... March 24.   Peterson, who brings more than ... John Smither , who is retiring at the end ... an advisory capacity. Peterson joins Sienna from Novan, Inc., ...
(Date:3/23/2017)... 2017 Research and Markets has announced ... report to their offering. ... The Global Market for Bioproducts Should ... at a CAGR of 8.9%, This research ... into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
Breaking Biology Technology:
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):